Curative Biotechnology, Inc. (CUBTD)

Market Cap	12.80M -9.9%
Revenue (ttm)	n/a
Net Income	-2.84M
EPS	-0.42
Shares Out	7.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,053
Average Volume	1,381
Open	1.800
Previous Close	1.200
Day's Range	1.638 - 1.850
52-Week Range	0.031 - 2.250
Beta	1.41
RSI	72.03
Earnings Date	Apr 15, 2026

About Curative Biotechnology

Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licen...

• Industry: Offices of Holding Companies, Not Elsewhere Classified
• Founded: 1995
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: CUBTD